A study in high-risk, maximally pretreated patients to determine the potential use of PCSK9 inhibitors at various thresholds of total and LDL cholesterol levels
Conclusions
We determined that the proportion of patients eligible for a PCSK9 inhibitor at various TC and LDL-c levels is modest. This may reflect the use of all available statins in UK lipid clinics often at non-daily frequency. We suggest that cost-effective use of PCSK9 inhibitors requires prescribing being restricted to clinicians working in specialised lipid clinics.
Source: Postgraduate Medical Journal - Category: Journals (General) Authors: Groves, C., Shetty, C., Strange, R. C., Waldron, J., Ramachandran, S. Tags: Original article Source Type: research
More News: Cardiology | Cardiovascular | Cholesterol | General Medicine | Heart | Statin Therapy | Study | Vytorin | Zetia